Site-specific attachment to recombinant antibodies via introduced surface cysteine residues
John R. Adair(UCB Pharma (United Kingdom)), Raymond J. Owens(Rosalind Franklin Institute), Andrew T. Millican, David J. King(Regulus Therapeutics (United States)), Nigel Whittle, Geoffrey Yarranton
Cited by 66
Related Papers
A versatile ligation-independent cloning method suitable for high-throughput expression screening applications
|Nucleic Acids Research|2007|571
High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker
|Nature Biotechnology|1992|465
A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody
|Molecular Immunology|1993|243
Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.
|PubMed|1996|212
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
|Nature Communications|2021|154